Contact Us marketing@medicilon.com
Medicilon Logo
|
search icon search icon 中 contact icon menu icon
Medicilon Logo
|
search icon close search icon 中 contact icon menu icon
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
Over 20 years of experience in R&D
Learn more
01 Drug Discovery
Chemistry Research
Biology Research
Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates
Active Pharmaceutical Ingredients
Pharmaceutical preparation
Analytical Method Development and Quality Control
CMC Filings
Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics
Drug Safety Evaluation
DMPK
Bioanalysis
IND Filings
01 One-stop Integrated Services
Drug Discovery Platform
Pharmaceutical Research Platform
Preclinical Research Services
Botanical Drug Preclinical R&D Technology Platform
02 Innovative Drug Services
ADC R&D Service Platform
PROTAC R&D Service Platform
mRNA Vaccine Bioanalysis Platform
Non-clinical Research for Cellular Immunotherapies
Nucleic Acid Drug R&D Platform
Peptide Drug Conjugate (PDC) R&D Service Platform
Antibody R&D Service
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection Platform
Metabolite Identification (MetID) Service Platform
Drug Forming Research Platform
Flow Cytometry Technology Platform
SEND Format Conversion Platform
Flow Sorting Platform
NanoString nCounter Detection Platform
Routes of Drug Administration Platform
04 Drug Efficacy Evaluation for Common Diseases
IO Pharmacodynamic Model Evaluation Platform
Pharmacodynamic Evaluation Model Platform for Inflammatory and Immune Diseases
Rodent Cerebrovascular Disease Drug Efficacy Evaluation System
05 Advanced Preparation R&D
Inhalation drug R&D platform
Ophthalmic drug R&D platform
Skin Topical Preparation R&D Platform
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service
GLP-1 New Drug R&D Service
KRAS-targeted Drugs R&D Service
CAREERS
Talent Development
Recruitment
Talent Development
Talent Development
Recruitment
Recruitment
News
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
2024-07-22Medicilon Events
The Shanghai Overseas Returned Scholars Association invites the Dutch PhD delegation to visit Medicilon, exploring paths for innovative development together
On July 4th, the Shanghai Overseas Returned Scholars Association invited the Dutch PhD delegation to visit the Chuansha campus of Shanghai Medicilon Inc. (Medicilon) and held discussions with Medicilon's Founder and CEO, Chunlin Chen, among others.
Learn more
2024-07-22Medicilon Events
5th consecutive win! Medicilon once again made the list of "Top 20 Chinese R&D CRO Enterprises in 2024"
Medicilon stood out among hundreds of pharmaceutical enterprises and was honored with the "Top 20 Chinese R&D CRO Enterprises in 2024" award.
Learn more
INVESTORS
Stock Information
Investment Contact
Medicilon 688202
RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
U.S.

Address: 470 Wildwood Ave, Woburn, MA 01801 (America)

Tel: +1(626)986-9880

UK

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Close

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888 | Website Map

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888|Website Map
关闭
中
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsMedicilon Events

Medicilon Events

Hot information：
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon FTE services & FFS services - flexible and efficient cooperation model| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon
Jan 24,2022
Medicilon Assisted DAC Biotechnology's Fourth ADC Drug DXC007 Getting Approved for Clinical Use
On December 28, 2021, Hangzhou DAC Biotechnology Co., Ltd. (DAC Biotech) DXC007 project was successfully approved for clinical trials. DXC007 is the fourth ADC drug approved for clinical use by DAC Biotech, and it is also the fourth ADC drug that Shanghai Medicilon Inc. (Medicilon) to help DAC Biotech successfully getting approval.
More
Medicilon Assisted DAC Biotechnology's Fourth ADC Drug DXC007 Getting Approved for Clinical Use
Jan 11,2022
Medicilon Assisted Regor Therapeutics Group's New-generation Tumor-targeting Inhibitor RGT-419B Getting Approved for Clinical Use
On December 28, 2021, the new generation of CDK2/4/6 small molecule inhibitor RGT-419B independently developed by Regor Therapeutics Group (Regor) was approved by the U.S. Food and Drug Administration (FDA).
More
Medicilon Assisted Regor Therapeutics Group's New-generation Tumor-targeting Inhibitor RGT-419B Getting Approved for Clinical Use
Jan 10,2022
Bao Pharmaceutical and Medicilon reached a strategic collaboration
On December 17, 2021, Shanghai Bao Pharmaceutical Co., Ltd. (Bao) and Shanghai Medicilon Inc. (Medicilon) signed an innovative drug IND R&D service strategy collaboration agreement.
More
Bao Pharmaceutical and Medicilon reached a strategic collaboration
Jan 04,2022
Recording the Growth of Medicilon in 2021
This year, Medicilon, with persistent belief, courageously and innovatively, pursued quality, and gave birth to the power of joint growth. Today, we take you to review the 2021 and witness the growth and progress of Medicilon!
More
Recording the Growth of Medicilon in 2021
Dec 20,2021
Medicilon won the 2020 "Golden Bull Science and Technology Innovation Award"
On December 20, China Securities Journal announced the list of the 23rd (2020) "Golden Bull Awards" for listed companies. Shanghai Medicilon Inc. (Medicilon) won the 2020 "Golden Bull Science and Technology Innovation Award."
More
Medicilon won the 2020 "Golden Bull Science and Technology Innovation Award"
Nov 24,2021
Two Innovative Service Platforms of Medicilon were Selected as Shanghai International Service Trade Demonstration project
Recently, the "2021 Yangpu Service Trade Digital Transformation Forum” under the guidance of the Shanghai Municipal Commission of Commerce and the People's Government of Yangpu District was grandly held.
More
Two Innovative Service Platforms of Medicilon were Selected as Shanghai International Service Trade Demonstration project
Nov 24,2021
Dr. Chunlin Chen was Awarded the 2021 Super CEO of the Pharmaceutical and Health Industry
On November 16, the "2021 Jiemian Health Forum” hosted by Shanghai United Media Group and Jiemian News was successfully held.  As a major part of
More
Dr. Chunlin Chen was Awarded the 2021 Super CEO of the Pharmaceutical and Health Industry
Nov 24,2021
Medicilon is Included in the MSCI China Index!
On the November 12th, the international index compilation company MSCI announced the results of the November quarterly index review.  Shanghai Medicilon Inc. (stock code: 688202.SH)
More
Medicilon is Included in the MSCI China Index!
Nov 22,2021
Within 10 days, three Bispecific Antibody Drugs Assisted by Medicilon were Approved!
On October 19, Bio-Thera's new double-antibody drug BAT7104 was granted implicit approval for clinical trials.
More
Within 10 days, three Bispecific Antibody Drugs Assisted by Medicilon were Approved!
Oct 28,2021
[Medicilon Assist] Bio-Thera's Bispecific Antibody BAT7104 has been Approved for Clinical Trials
​Recently, Bio-Thera's PD-L1/CD47 bispecific antibody BAT7104 injection has been granted implicit permission for clinical trials, and the approved indication is advanced malignant tumors. It is reported that BAT7104 has started overseas clinical research.
More
[Medicilon Assist] Bio-Thera's Bispecific Antibody BAT7104 has been Approved for Clinical Trials
Oct 21,2021
AI Empowers the Development of Innovative Tumor Drugs! Medicilon and MindRank Reached a Strategic Cooperation
On October 21, 2021, Shanghai Medicilon and Hangzhou MindRank signed a strategic agreement in Chuansha Park of Medicilon.
More
AI Empowers the Development of Innovative Tumor Drugs! Medicilon and MindRank Reached a Strategic Cooperation
Oct 21,2021
Medicilon was Awarded The "Golden Horse Award-2021 Best Preclinical CRO/CDMO Enterprise"
From October 19-21, 2021, a grand event that has attracted the attention of the national pharmaceutical industry, "2021 Nanjing International Summit on Innovation and Investment
More
Medicilon was Awarded The "Golden Horse Award-2021 Best Preclinical CRO/CDMO Enterprise"
Stock Code
688202

Global

Address: 470 Wildwood Ave, Woburn, MA 01801 (America)

Tel: +1(626)986-9880(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->